Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. 1 Centers for Disease Control and Prevention. An update on cancer deaths in the United States. Available at: https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm. Accessed October 27, 2022. Google Scholar Around 16% of patients present with localized disease, of whom around 25% will not be surgical candidates. 2 National Cancer Institute. SEER cancer statistics review 1975-2015. Available at: https://seer.cancer.gov/archive/csr/1975_2015/results_merged/sect_15_lung_bronchus.pdf. Accessed February 18, 2023. Google Scholar ,3 Choi JI. Medically inoperable stage I non-small cell lung cancer: Best practices and long-term outcomes. Transl Lung Cancer Res. 2019; 8: 32-47 Crossref PubMed Scopus (13) Google Scholar In 2003, lung SABR for medically inoperable patients was first studied in the United States by Timmerman and colleagues with excellent safety and efficacy. 4 Timmerman R Papiez L McGarry R et al. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003; 124: 1946-1955 Abstract Full Text Full Text PDF PubMed Scopus (616) Google Scholar Despite durable local control (LC), longer follow-up revealed metachronous locoregional and distant failure rates up to 30% to 40%. 5 Timmerman RD Hu C Michalski J et al. Long-term results of RTOG 0236: A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014; 90: S30 Abstract Full Text Full Text PDF Google Scholar ,6 Videtic GM Paulus R Singh AK et al. Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2019; 103: 1077-1084 Abstract Full Text Full Text PDF PubMed Scopus (166) Google Scholar